Ignite Creation Date:
2024-05-06 @ 7:22 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT05998447
Status:
RECRUITING
Last Update Posted:
2024-03-21
First Post:
2023-08-01
Brief Title:
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
Sponsor:
Genome Company
Organization:
Genome Company
Organization Data
Organization:
Genome Company
Class:
INDUSTRY
Study ID:
GNC GEN001-202
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Genome Company
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |